Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Priming and Propagating Anti-tumor Immunity: Focal Hypofractionated Radiation for in Situ Vaccination and Systemic Targeted Radionuclide Theranostics for Immunomodulation of Tumor Microenvironments

Seminars in Radiation Oncology(2020)10.1016/j.semradonc.2019.12.008Source: DataRank Database

Priming and Propagating Anti-tumor Immunity: Focal Hypofractionated Radiation for in Situ Vaccination and Systemic Targeted Radionuclide Theranostics for Immunomodulation of Tumor Microenvironments is a research paper published in Seminars in Radiation Oncology (2020). On theSindex it has a DataRank of 0. It has been cited 33 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access33 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (11 grants)OA: hybridTopics (27)IDs (PubMed, PMC)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (2)

Zachary S. Morris ORCID,Justin C. Jagodinsky ORCID

Live enrichment

PubMed:32381297 PMC:PMC7286051

NCI NIH HHS

Grant: U01 CA233102

NCATS NIH HHS

Grant: TL1 TR002375

NCI NIH HHS

Grant: P30 CA014520

NIH HHS

Grant: DP5 OD024576

NIDCR NIH HHS

Grant: P50 DE026787

NIGMS NIH HHS

Grant: T32 GM008692

National Institutes of Health

Grant: 5DP5OD024576-02

Combining Radiation and Tumor-specific AntIbody Therapies to Elicit in Situ Tumor Vaccination

National Institutes of Health

Grant: 5T32GM008692-22

Integrated Training For Physician-Scientists

National Institutes of Health

Grant: 5P50DE026787-02

Head and Neck Cancer SPORE at the University of Wisconsin

National Institutes of Health

Grant: 5P30CA014520-18

CANCER CENTER SUPPORT

National Institutes of Health

hybridLicense: cc-by-nc-nd

publisherhttps://www.sciencedirect.com/science/article/pii/S1053429619300839/pdf

publisherhttps://api.elsevier.com/content/article/PII:S1053429619300839?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1053429619300839?httpAccept=text/plain

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7286051

Unpaywallhttps://doi.org/10.1016/j.semradonc.2019.12.008

Fields of Study

0301 basic medicine03 medical and health sciences0302 clinical medicine

MeSH Terms

AnimalsHumansDisease Models, AnimalAntibodies, MonoclonalAntigens, NeoplasmCytokinesVaccinationCombined Modality TherapyImmunomodulationTumor MicroenvironmentRadiation Dose HypofractionationImmune Checkpoint Inhibitors

Keywords

VaccinationAntibodies, MonoclonalCombined Modality TherapyImmunomodulationDisease Models, AnimalAntigens, NeoplasmTumor MicroenvironmentAnimalsCytokinesHumansRadiation Dose HypofractionationImmune Checkpoint Inhibitors

Sustainable Development Goals

SDG 3: 3. Good health

Priming and Propagating Anti-tumor Immunity: Focal Hypofractionated Radiation for in Situ Vaccination and Systemic Targeted Radionuclide Theranostics for Immunomodulation of Tumor Microenvironments

FAIR Checklist

Authors (2)

Funding (11 grants)

Open Access

Topics

Annotations (Europe PMC)